Letter in reply

Affiliations

¹ EVERSANA™, 204-3228 South Service Road, Burlington, Ontario, L7N 3H8, Canada.
² EVERSANA™, 207-275 Charlotte Street, Sydney, Nova Scotia, B1P 1C6, Canada.
³ Novartis Pharma AG, Basel, Switzerland.
⁴ Department of Neurology, University Hospital Münster, Westfälische-Wilhelms-University Münster, Münster, Germany.

Free article

Comment

Imtiaz A Samjoo et al. J Comp Eff Res. 2021 Dec.

Free article

. 2021 Dec;10(17):1267-1269.

doi: 10.2217/cer-2021-0203. Epub 2021 Oct 5.

¹ EVERSANA™, 204-3228 South Service Road, Burlington, Ontario, L7N 3H8, Canada.
² EVERSANA™, 207-275 Charlotte Street, Sydney, Nova Scotia, B1P 1C6, Canada.
³ Novartis Pharma AG, Basel, Switzerland.
⁴ Department of Neurology, University Hospital Münster, Westfälische-Wilhelms-University Münster, Münster, Germany.

No abstract available

Keywords: disease-modifying therapies; indirect treatment comparison; network meta-analysis; ofatumumab; relapsing multiple sclerosis.

Comment on

Comparison of ofatumumab and other disease-modifying therapies for relapsing multiple sclerosis: a network meta-analysis.
Samjoo IA, Worthington E, Drudge C, Zhao M, Cameron C, Häring DA, Stoneman D, Klotz L, Adlard N. Samjoo IA, et al. J Comp Eff Res. 2020 Dec;9(18):1255-1274. doi: 10.2217/cer-2020-0122. Epub 2020 Oct 22. J Comp Eff Res. 2020. PMID: 33090003
Letter to the Editor: comparison of ofatumumab and other disease-modifying therapies for relapsing multiple sclerosis: a network meta-analysis.
Parekh K, Watkins C. Parekh K, et al. J Comp Eff Res. 2021 Dec;10(17):1265-1266. doi: 10.2217/cer-2021-0123. Epub 2021 Oct 5. J Comp Eff Res. 2021. PMID: 34608807 No abstract available.